Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Erimos Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00259818
First received: November 30, 2005
Last updated: January 23, 2008
Last verified: January 2008
  Purpose

This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies. There have been no previous human studies of intravenous (into one's vein) EM-1421 treatment; however, lab research (research in test tubes and/or animals) suggests that EM-1421 has shown some activity against tumors in animals. This activity in animal models suggests that EM-1421 may be a useful chemotherapy for human cancer.

The primary objective of this study is to determine the safety and maximum tolerated dose of EM-1421 given by intravenous infusion. The efficacy of the treatment will also be measured.


Condition Intervention Phase
Cancer
Drug: EM-1421
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Refractory Malignant Tumors

Resource links provided by NLM:


Further study details as provided by Erimos Pharmaceuticals:

Primary Outcome Measures:
  • Safety
  • Maximum tolerated dose

Secondary Outcome Measures:
  • Pharmacokinetic parameters
  • Pharmacodynamic parameters
  • Anti-tumor activity of regimen
  • Feasibility of regimen

Estimated Enrollment: 30
Study Start Date: December 2005
Study Completion Date: January 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects ≥ 18 years of age.
  • Subjects with documented evidence of cancer with clinically evaluable disease. Cancer can be recurrent after primary treatment with surgery, radiation therapy, and/or chemotherapy and may include those patients for whom no standard or curative therapy exists.
  • Measurable tumor by imaging (computed tomography [CT] per Response Evaluation Criteria in Solid Tumors [RECIST] criteria).
  • Life expectancy of at least 3 months in the Investigator's opinion.
  • Negative pregnancy test, if in women of childbearing potential, within one week of starting therapy.
  • Subjects who have provided written informed consent to participate in the study.
  • ECOG performance status of 0, 1, or 2.
  • Absolute neutrophil ≥ 1500 cells/µL, hemoglobin ≥ 9 gm/dl, platelets ≥ 100,000/µL, ALT/AST ≤ 3 x ULN (upper limit of the normal range) unless involved with tumor then < 5 x ULN, bilirubin ≤ 1.5 x ULN, and creatinine ≤ 1.5 x ULN.

Exclusion Criteria:

  • Women who are pregnant or breast-feeding (women of child-bearing potential must have a negative serum pregnancy test within one week of entering the study.)
  • Women of child-bearing potential who are unwilling to use two medically acceptable forms of contraception during the course of the study (surgical sterilization, approved hormonal contraceptives, or barrier method with spermicide).
  • Treatment with a prior investigational agent within 28 days of entering the study.
  • Subjects unable to comply with the study requirements.
  • Subjects with a known sensitivity to any of the study medication components.
  • Prior chemotherapy, radiation therapy, or surgery for the primary tumor within 28 days of dosing and/or has not recovered from prior therapy toxicities - with the exception of non-experimental chronic hormone therapy for currently progressive metastatic prostate cancer. However, local radiation to a site of symptomatic disease will be acceptable if it has been completed at least 14 days prior to study drug initiation and subjects have recovered from all treatment-related side effects.
  • Subjects exhibiting any of the following: a marked baseline prolongation of QT/QTc interval (repeated demonstration of a calculated QTc interval > 450), a history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome), and subjects unable or unwilling to refrain from using medications that are known to prolong the QT/QTc ratio during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00259818

Locations
United States, Arizona
Premiere Oncology of Arizona
Scottsdale, Arizona, United States
United States, New York
Albert Einstein College of Medicine
Bronx, New York, United States
United States, Tennessee
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Sponsors and Collaborators
Erimos Pharmaceuticals
Investigators
Investigator: Neil Frazer, MB Erimos Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00259818     History of Changes
Other Study ID Numbers: EM-1421 #101
Study First Received: November 30, 2005
Last Updated: January 23, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Erimos Pharmaceuticals:
Refractory
Solid Tumors

ClinicalTrials.gov processed this record on September 16, 2014